Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

398 publications
Année de publication :
Réseaux :

The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on…

Although some studies suggested that disruption of the Hippo signaling pathway is associated with osteosarcoma progression, the molecular mechanisms by which YAP regulates primary tumor growth is not fully clarified.

  • Ref: Cancers (Basel). 2020 Dec 20;12(12):3847.
  • Année de publication : 2020
  • Auteurs : Morice S, Mullard M, Brion R, Dupuy M, Renault S, Tesfaye R, Brounais-Le Royer B, Ory B, Redini F, Verrecchia F.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs » & « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

In Vivo Albumin-Binding of a C-Functionalized Cyclam Platform for 64 Cu-PET/CT Imaging in Breast Cancer Model.

An improved glucose-chelator-albumin bioconjugate (GluCAB) derivative, GluCAB-2Mal , has been synthesized and studied for in vivo 64 Cu-PET/CT imaging in breast cancer mice models together with its first-generation analogue GluCAB-1Mal . The radioligand works on the principle of tumor targeting through the enhanced permeability and retention (EPR) effect with a supportive role played by glucose metabolism. [64 Cu]Cu-GluCAB-2Mal (99 % RCP) exhibited high serum stability with immediate binding to serum proteins.

  • Ref: ChemMedChem. 2020 Nov 15.
  • Année de publication : 2020
  • Auteurs : Le Bihan T, Driver CHS, Ebenhan T, Le Bris N, Zeevaart JR, Tripier R.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »
Lire la publication

Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s…

Osteosarcoma (OS) and Ewing’s sarcoma (ES) are the most common malignant bone tumors in children and adolescents. In many cases, the prognosis remains very poor. The Sonic hedgehog (SHH) signaling pathway, strongly involved in the development of many cancers, regulate transcription via the transcriptional factors Gli1-3.

  • Ref: Cancers (Basel). 2020 Nov 19;12(11):3438.
  • Année de publication : 2020
  • Auteurs : Mullard M, Cadé M, Morice S, Dupuy M, Danieau G, Amiaud J, Renault S, Lézot F, Brion R, Thepault RA, Ory B, Lamoureux F, Corre I, Brounais-LeRoyer B, Rédini F, Verrecchia F.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs » & « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

GETUG-AFU 17 : étude de phase III randomisée comparant la radiothérapie adjuvante à la radiothérapie de…

La radiothérapie adjuvante (aRT) réduit le risque de rechute biochimique chez les patients atteints d’un cancer de la prostate traités par une prostatectomie radicale (RP). L’étude GETUG-AFU 17 a comparé l’efficacité et la toxicité de l’aRT par rapport à la radiothérapie de rattrapage précoce (sRT), associée à un traitement hormonal.

  • Ref: Prog Urol. 2020 Nov;30(13):733-734.
  • Année de publication : 2020
  • Auteurs : Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche S, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihou M, Soulié M, Richaud P.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »
Lire la publication

Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A…

Peritoneal carcinomatosis extent in ovarian cancer is difficult to evaluate by imaging techniques even though it determines the surgical complexity and survival. The aim of this study was to estimate the accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-PET CT (Positron-emission tomography coupled with Computerised Tomography) performed before any treatment, in the diagnosis of the extent of peritoneal carcinomatosis.

  • Ref: J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101867.
  • Année de publication : 2020
  • Auteurs : Delvallée J, Rossard L, Bendifallah S, Touboul C, Collinet P, Bricou A, Huchon C, Lavoue V, Body G, Ouldamer L.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Comparison of survival outcomes between laparoscopic and abdominal radical hysterectomy for early-stage cervical cancer: A French…

Objectives: A recent randomized controlled trial has reconsidered the use of laparoscopy for treating patients with early-stage cervical cancer with radical hysterectomy (RH). We aimed to evaluate if surgical approach had an impact on surgical and oncological outcomes in these patients in a French setting.

  • Ref: J Gynecol Obstet Hum Reprod. 2020 Dec 16;50(2):102046.
  • Année de publication : 2020
  • Auteurs : Zaccarini F, Santy A, Dabi Y, Lavoue V, Carcopino X, Bendifallah S, Benbara A, Collinet P, Canlorbe G, Raimond E, Graesslin O, Ouldamer L, Daraï E, Huchon C, Golfier F, Touboul C, Bolze PA.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the…

The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer.

  • Ref: J Clin Med. 2020 Nov 12;9(11):3646.
  • Année de publication : 2020
  • Auteurs : de Foucher T, Hennebert C, Dabi Y, Ouldamer L, Lavoué V, Dion L, Canlorbe G, Bolze PA, Golfier F, Akladios C, Lecointre L, Kerbage Y, Collinet P, Bricou A, Carcopino X, Huchon C, Raimond E, Graesslin O, Owen C, Touboul C, Ballester M, Darai E, Bendifallah S.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Sarcoma treatment in the era of molecular medicine.

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies.

  • Ref: EMBO Mol Med. 2020 Nov 6;12(11):e11131.
  • Année de publication : 2020
  • Auteurs : Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, Di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, Morales-Molina Á, Musa J, Ohmura S, Ory B, Pereira-Silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-Jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment.

  • Ref: J Clin Invest. 2020 Nov 2;130(11):6109-6123.
  • Année de publication : 2020
  • Auteurs : Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell…

The role of Epigenetics in Epithelial Mesenchymal Transition (EMT) has recently emerged. Two epigenetic enzymes with paradoxical roles have previously been associated to EMT, EZH2 (Enhancer of Zeste 2 Polycomb Repressive Complex 2 (PRC2) Subunit), a lysine methyltranserase able to add the H3K27me3 mark, and the histone demethylase KDM6B (Lysine Demethylase 6B), which can remove the H3K27me3 mark.

  • Ref: Cancers (Basel). 2020 Dec 5;12(12):3649.
  • Année de publication : 2020
  • Auteurs : Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication